within Pharmacolibrary.Drugs.ATC.A;

model A10BF03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.04,
    Cl             = 0.00024333333333333333,
    adminDuration  = 600,
    adminMass      = 0.2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0057,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BF03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Voglibose is an oral alpha-glucosidase inhibitor used to improve postprandial blood glucose levels in patients with type 2 diabetes mellitus. It works by delaying the absorption of glucose from the intestines. Voglibose is approved and used in several Asian countries for diabetes management, but is not widely approved in the US or EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Imamura, A, et al., &amp; Imai, Y (2013). Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes. <i>Diabetes therapy : research, treatment and education of diabetes and related disorders</i> 4(1) 41–49. DOI:<a href=\"https://doi.org/10.1007/s13300-012-0016-5\">10.1007/s13300-012-0016-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23307267/\">https://pubmed.ncbi.nlm.nih.gov/23307267</a></p></li><li><p>Kim, HS, et al., &amp; Shin, JG (2014). Effect of voglibose on the pharmacokinetics of metformin in healthy Korean subjects. <i>International journal of clinical pharmacology and therapeutics</i> 52(11) 1005–1011. DOI:<a href=\"https://doi.org/10.5414/CP202160\">10.5414/CP202160</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25161160/\">https://pubmed.ncbi.nlm.nih.gov/25161160</a></p></li><li><p>Kaku, K (2014). Efficacy of voglibose in type 2 diabetes. <i>Expert opinion on pharmacotherapy</i> 15(8) 1181–1190. DOI:<a href=\"https://doi.org/10.1517/14656566.2014.918956\">10.1517/14656566.2014.918956</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24798092/\">https://pubmed.ncbi.nlm.nih.gov/24798092</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BF03;
